CXCL10 and melanoma: This suppression could be particularly detrimental in cancers such as melanoma, non-small cell lung cancer (NSCLC) or renal cell carcinoma, where high intratumorally CXCL10 expression is associated with a better prognosis and increased response to immune checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 antibodies.90,91 In addition, CXCL10 has angiostatic properties, and its blockade may inadvertently promote angiogenesis, allowing tumors to grow and metastasize more efficiently.